ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
IPO Year:
Exchange: NASDAQ
Website: https://www.promisneurosciences.com
4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)
SC 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)
SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)
SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)
SC 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)
SC 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)
SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)
SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)
SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)
SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)
8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)
8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)
10-Q - ProMIS Neurosciences Inc. (0001374339) (Filer)
8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)
8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)
8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)
DEFA14A - ProMIS Neurosciences Inc. (0001374339) (Filer)
DEF 14A - ProMIS Neurosciences Inc. (0001374339) (Filer)
EFFECT - ProMIS Neurosciences Inc. (0001374339) (Filer)
S-3 - ProMIS Neurosciences Inc. (0001374339) (Filer)
CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. "We continue to make significant progress as we are nearing completion of the Phase 1a single ascending dose clinical trial of PMN310 in Alzheimer's disease and remain on track to report top-
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the fiscal year ended December 31, 2023 and provided a corporate update. "I am pleased to have taken the helm of ProMIS at the beginning of 2024 and am proud of the meaningful progress the team has made to date as ProMIS made the transition to a clinical deve
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced a strategic leadership change. The Company's Board of Directors appointed Neil Warma, a highly-qualified biotechnology industry executive and ProMIS Board member, as interim Chief Executive Officer to succeed Gail Farfel, Ph.D., who has stepped down to pursue other opportunities. Mr. Warma's appoint
Presented compelling preclinical data supporting therapeutic potential of PMN310 to treat Alzheimer's disease, and the promise of disease prevention with a computationally derived Alzheimer's disease vaccine candidate at AAIC 2023 TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the second quarter ended June 30, 2023 and
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 30, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX:PMN) (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), is pleased to announce the Annual Meeting of Shareholders was held by virtual web-cast meeting, on Thursday, June 29, 2023 at 9:30 a.m. (Eastern time). With 51.23% of common shares represented at the Meeting, and 93.51% series 1 preferred shares represented at the meeting, shareholders approved all resolu
Closed US$7.4 million private placementAppointed Gail Farfel, Ph.D., as Chief Executive OfficerContinued progress toward investigational new drug (IND) submission for PMN310 to pursue Alzheimer's disease indication TORONTO, Ontario and CAMBRIDGE, Massachusetts, Nov. 14, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX:PMN) (NASDAQ:PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic misfolded proteins implicated in the development of neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced its third quarter 2022 financial results and
TORONTO, Ontario and CAMBRIDGE, Massachusetts , Sept. 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN) (TSX:PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, announced today that it has appointed Gail M. Farfel, Ph.D., as Chief Executive Officer, effective September 19, 2022. "The past 18 months have been transformative for ProMIS," stated Eugene Williams, ProMIS Chairman and Co-Founder. "During this period, we achieved strong capital formation led by a prominent group of Boston-based investors, and with tremen
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 15, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN) (NASDAQ:PMN) ("ProMIS" or the "Company"), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three months ended June 30, 2022. "Q2 was another quarter of strong progress for ProMIS Neurosciences," according to Gene Williams, Chairman and CEO. "We completed the work necessary to list on Nasdaq, effective July 7. We want to thank our shareholders for their strong
CAMBRIDGE, Massachusetts, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that its Chief Executive Officer, Neil Warma, issued the following letter to the Company's shareholders. Dear ProMIS Shareholders, In my first year as the Chief Executive Officer of ProMIS, we made great strides advancing our mission-driven innovation focused on developing precision-t
CAMBRIDGE, Massachusetts, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b clinical trial (PRECISE-AD) evaluating its lead therapeutic candidate, PMN310, in Alzheimer's disease (AD). PMN310, a humanized IgG1 antibody, is engineered to selectively target toxic oligomers of amyloid-beta (AβO)—which are believed to be a key driver of Alzheimer's pathology—while avoiding interaction with plaque deposits. This mechanism is designed to help reduce the risk of amyloid-related imaging abnormalities (ARIA), a
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 1:20 p.m. ET in Coral Gables, FL. A live webcast of the fireside chat may be accessed by visitin
Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential target engagement in patients with Alzheimer's disease On track to initiate Phase 1b clinical trial in patients with Alzheimer's disease by end of 2024 CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic late
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Wednesday, November 13, 2024 at 10:00 a.m. ET in Boston, MA. A live webcast of the fireside chat may be accessed by
Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement Initiation of Phase 1b clinical trial in Alzheimer's disease patients planned for year-end 2024 CAMBRIDGE, Massachusetts and TORONTO, Ontario, Oct. 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today presented positive results from all five cohorts from the Phase 1a, sin
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that preclinical data supporting the potential role of its lead product candidate, PMN310, as a treatment for AD will be highlighted in an oral presentation at the 4th International Conference on Cognitive & Behavioral Neurosciences (ICBN) taking place from September 12-13, 2024 in Lisbon, Portugal
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 05, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate at the H.C. Wainwright 26th Annual Global Investment Conference and will conduct one-on-one meetings from September 9 – 10, 2024. Mr. Warma will deliver an overview of the Company's pioneering antibody therapeutics that selectively target toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease, amyot
Reported positive topline data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease that met objectives for tolerability, safety and pharmacokinetics Secured up to $122.7 million in private placement financing from leading healthcare specialty funds to advance Phase 1b study of PMN310 in Alzheimer's disease patients in second half 2024 CAMBRIDGE, Massachusetts and TORONTO, Ontario, Aug. 08, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disea
Body of work supports targeting misfolded proteins as a therapeutic strategy for ALS with the potential to translate across multiple neurodegenerative diseases CAMBRIDGE, Massachusetts and TORONTO, Ontario , Aug. 06, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced the publication of two papers highlighting the role of toxic misfolded superoxide dismutase-1 (SOD1) aggregates in the pathogenesis of AL